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                            INTRODUCTION 
 
Lichen Planus is one of the most itchy dermatoses. It is prevalent   
worldwide with no social or climatic predilection. It affects the skin,  
mucous membrane, nails and hair. Itching is a constant feature of lichen  
planus and the lesions heal with pigmentation which may be persistent  
and intense in dark skinned people. Spontaneous remissions can occur  
after varying amounts of time. 
 
       An autoimmune mechanism has been proposed with the involvement 
of activated T cells directed against an unknown antigen in the skin or 
mucosa. Certain infections have also been associated with lichen planus 
but the cause and effect relationship remains controversial.  
 
        There are no evidence-based recommendations for the treatment of 
lichen planus. Many of the recommendations of the experts are based on 
their personal experience. Most of the published trials are observational 
and are not always prospective. Only a few randomized controlled trials 
have been performed. However treatment with medium to high-potency 
topical corticosteroids is generally recommended as the first-line therapy 
for localised lichen planus. 
 
          Topical Tacrolimus, a calcineurin inhibitor is used extensively in 
the treatment of atopic dermatitis. Unlike topical corticosteroids, it does 
not cause skin atrophy. Topical Tacrolimus in addition to its inhibitory 
effect on cytokine production causes alterations in epidermal antigen-
presenting dendritic cells that may result in decreased immunologic 
response to antigens. Topical tacrolimus has been used in oral lichen 
planus but to our knowledge not in cutaneous lichen planus except for a 
single case report.  
   
         The possible role of activated T cells in the pathogenesis of lichen 
planus as well as the extensive safety profile makes topical tacrolimus an 
attractive option for the treatment of cutaneous lichen planus. However 
there are no head to head comparisons of corticosteroids and tacrolimus 
in the treatment of lichen planus.  
 
      Towards this goal we performed a prospective, randomised, open 
label clinical trial comparing the therapeutic efficacy of a topical 
corticosteroid 0.05% halobetasol propionate with a topical calcineurin 
inhibitor 0.1% tacrolimus in adults with localised cutaneous lichen 
planus.  
 
         
 
REVIEW OF LITERATURE 
 
TERMINOLOGY: 
 Lichen planus is a unique inflammatory disorder characterized by             
flat–topped, polygonal, violaceous papules in the skin. It also affects the 
mucous membrane, nails and hair follicles.  
 LICHEN PLANUS is derived from the Greek word “Leichen” 
meaning “tree moss” and the Latin word “planus” meaning “flat”. The 
appearance of lichen planus has been likened to the scurfy, finely 
furrowed dry excrescences of the symbiotic vegetation known as lichen1. 
 The term “lichenoid” is used by clinicians to describe flat – topped, 
shiny papular eruptions resembling lichen planus or by histopathologists 
to describe a type of tissue reaction consisting principally of basal cell 
liquefaction and a band like inflammatory infiltrate in upper dermis2. 
HISTORY: 
 The term ‘lichen planus’ was introduced by William James Erasmus  
 Wilson in 1869 to describe the condition which had been previously 
 named ‘lichen ruber’ by Hebra3. 
 Louis Fredric Wickham described the characteristic striae on lichen 
 planus lesions in 1895.  
 The histological findings were defined by Darier in 19094.  
 Graham Little described scalp involvement in 1919.  
PATHOGENESIS  
 LP is thought to be an immunologically mediated disorder5 where 
CD8+cytotoxic T cells recognize an antigen (currently unknown) 
associated with the MHC class I on lesional keratinocytes and lyse them6.  
CD4 + and CD8+ T cells are found in the lesional skin of lichen planus. 
With disease progression, majority of lymphocytes in the infiltrate of 
lichen planus are CD8+ and CD45 RO (memory) cells & express the αβ 
T–cell receptor and in a minority, the γ-δ receptor  (which is not normally 
found in healthy skin). CD8+ cells are responsible for development of 
apoptosis. T helper cells may also become activated, via antigen 
presenting cells such as langerhans cells or epidermal keratinocytes in 
association with MHC class II and specific cytokines. The T helper 
lymphocytes may propagate CD8+ cytotoxic lymphocytes through 
cellular  co-operation & release of cytokines.  
 The epithelial-lymphocyte interaction can be divided into 3 stages.  
1. Antigen recognition 2. Lymphocyte activation 3. Keratinocyte 
apoptosis1.  
1. Lichen planus – specific antigen recognition: 
 The nature of the antigen is unknown. It may be an auto reactive 
peptide or an exogenous antigen such as an altered protein, drug, contact 
allergen, viral or infectious agent, or an unidentified immunogenic 
target7. It may act as a hapten to initiate the process. 
 2. Cytotoxic T – Lymphocyte Activation 
 Following antigen recognition, CD8 + T cells are activated and 
undergo lesional tissue clonal expansion, leading to oligoclonal & 
occasionally monoclonal proliferation. Activated lymphocytes (both 
helper and cytotoxic) release cytokines such as IL-2, IL–4, IL–10, IFN–γ, 
TNF-α and TGFβ, that attracts lymphocytes to the epithelium & regulates 
their activity. The balance between lymphocyte activation and 
downregulation determines the clinical disease.  
             IFN–γ produced by the T helper cells i) induces keratinocytes to 
produce lymphotoxin α and TNF-α & to upregulate MHC class II thus 
increasing interactions with CD4 + T cell ii) upregulates expression of 
ICAM–1 & VCAM–1 by basal keratinocytes, langerhans cells and other 
macrophage dendritic cells.  
 Laminin 5 & collagen IV, VII are increased in lichen planus 
lesions and act as ligands for β1 integrin present on surface of 
lymphocytes thus facilitating attachment of lymphocytes with the 
basement membrane. Integrin α3, present on activated skin homing T 
cells may localize the cells to the epidermal–dermal interface & basement 
membrane, which contains epiligrin/laminin–5, a ligand for this integrin8. 
This close interaction between the lymphocytes and basement membrane, 
activates matrix metalloproteinase-9 (MMP-9) produced by lymphocytes 
resulting in apoptosis, basement membrane disruption, duplication & 
subepidermal cleft formation.  
 Keratinocytes produce IL-1β, IL-4, IL-6, GM-CSF, TNFα, which 
further activates tissue macrophages & peripheral blood mononuclear 
cells and upregulates cell surface adhesion molecules & migration 
activity.  
3. Keratinocyte Apoptosis  
         Possible mechanisms for keratinocyte apoptosis are 1) T cell 
secreted TNFα binding to TNFαR1 receptor on the keratinocyte surface 
2) T cell surface CD95L (Fas ligand) binding to Fas on the keratinocyte 
3)T cell secreted granzyme B / perforin entering the keratinocytes by 
inducing pores: all these activiate the caspase cascade resulting in 
apoptosis of the keratinocytes7. 
 T cell secreted MMP–9 disrupts the basement membrane, thus 
blocking the cell survival signals to the keratinocytes & loss of this anti-
apoptotic mechanism induces apoptosis.  
GENETICS 
 There may be a genetic predisposition to develop lichen planus. 
Associations with HLA–3 & HLA–59, HLA–B710, HLA–28 with 
carbohydrate intolerance, HLA–DR1, HLA-DR10 and HLA-DRB1*0101  
have been reported. HLA–B8 is more common in patients with oral 
lichen planus and HLA–BW35 is strongly associated with cutaneous 
lichen planus1. A familial form of the disease exists11 and monozygotic 
twins may be affected12.  
VIRUSES 
 HCV RNA has been isolated from lesional skin in patients with 
lichen planus & chronic HCV infection13. Thus, an HCV related product 
has been postulated as a possible antigen in lichen planus. Lichen planus 
has been associated with human herpes virus type 7 replication14.  
DENTAL AMALGAMS: 
 The presence of amalgam or gold is not associated with an 
increased risk of oral LP, but corrosion of amalgams, and a ‘galvanic 
effect’ from dissimilar dental materials in continuous contact with the 
mucosa (bimetallism) is associated with elevated risk of oral LP15. 
MISCELLANEOUS CAUSES 
 LP has been induced by radiotherapy16. Anxiety, depression17 and 
stress18 may be risk factors for developing lichen planus.  
EPIDEMIOLOGY 
           LP has a worldwide distribution with no racial predisposition. 
0.22% to 1% of adult population is affected by cutaneous LP3.The 
incidence in India is 0.38%19.There is no sexual predilection1. Average 
age of onset is the 4th decade in males and 6th decade in females3. 
Association of lichen planus with blood group A has been proposed20. 
CLINICAL FEATURES  
MORPHOLOGY  
 Lichen planus is characterized by shiny, violaceous, flat-topped 
polygonal papules, varying in size from a pin–point to several 
centimeters. The 4 Ps– purple, polygonal, pruritic, papule are used to 
describe the clinical appearance of the lesions. White lines known as 
Wickham’s striae may traverse the surface of the papules, and are better 
visualized with a hand lens after applying oil, water or xylene. In the 
acute and evolving stages of the disease scratching, injury or trauma may 
induce an isomorphic response (Koebner response) 
 SITES 
 Lichen planus can affect any part of the body, but is most often 
seen on the volar aspect of the wrists, lumbar region, and around the 
ankles. The arms, legs, thighs, lower back, trunk, neck, oral cavity, 
genitalia, scalp, nails may also be affected. Face is usually spared in 
classical cases and palmoplantar involvement is unusual.  
 SYMPTOMS 
 Itching is a constant feature and ranges from mild to continuous 
severe itching. Hypertrophic lesions usually have severe itching. Often, 
there is no evidence of scratching as the patient rubs, rather than scratches 
to gain relief.  
        Erosive lichen planus of the oral cavity can cause extreme pain. 
Patients with oral lesions may complain of discomfort, stinging or pain.  
 
NATURAL HISTORY  
 The onset is usually insidious. The papules are first erythematous 
and turn violaceous after a few weeks. The papules eventually flatten 
after a few months and are replaced by an area of hyperpigmentation that 
retains the shape of the lesion that persists for months or years. The 
pigmentation may be intense in dark skinned individuals.  
 New papules may continue to erupt. Some papules persist, enlarge 
& thicken to develop a roughened surface with prominent violaceous hue 
(hypertrophic LP). Lesions resolve with atrophy & scarring.  
CLINICAL VARIANTS 
 Variations can occur in the clinical presentation and may be 
categorized according to  
1) The configuration of lesions 2) the morphology 3) the site of 
involvement.  
CONFIGURATON OF LESIONS 
(i) Annular lichen planus: 
 They may be formed (i) either by groups of papules arranged in 
rings or (ii) by single, large papules clearing in the centre leaving behind 
an active margin. They are most commonly seen over the penis.  
(ii) Linear Lichen Planus 
 It constitutes 0.25% of the different clinical patterns21. Papules may 
develop in a linear pattern secondary to trauma (Koebnerisation). 
Sometimes, linear lesions follow a segmental / zosteriform pattern or 
lines of Blaschko22.  
 
MORPHOLOGY OF LESIONS  
(i)  Hypertrophic Lichen Planus / Lichen Planus Verrucosus): 
 Extremely pruritic, thick raised verrucous plaques are seen 
primarily on the shins and around the ankles. The lesions tend to be 
chronic and some lesions show central depigmentation surrounded by a 
hyperpigmented rim. They heal with hypo or hyperpigmentation & 
scarring. There are reports of Squamous Cell Carcinoma arising from 
long–standing lesions of hypertrophic LP23.  
(ii)  Atrophic Lichen Planus: Well demarcated papules or plaques with 
central atrophy are seen. Atrophy may result from faded annular lesions 
or resolved hypertrophic lesions especially on the lower legs.  
(iii)  Vesiculobullous Lichen Planus: 
 This is characterized by the development of vesicles and bulla 
within the lesions of lichen planus. They may suddenly appear during an 
acute flare–up of the disease. 
 
 
(iv)  Lichen Planus Pigmentosus:  
 This is a pigmentary disorder seen in India and the Middle East. 
Slate grey or brown macules are seen over the sun-exposed areas and the 
flexural folds24. Pigmentation may be diffuse, reticular, blotchy, or 
perifollicular. The mucous membranes, palms and soles are usually not 
involved and there may or may not be associated lichen planus papules.  
(v)  Actinic Lichen Planus (Lichen planus subtropicus / Lichen planus 
tropicus / Lichen planus Actinicus / Lichen Planus Atrophicus Annularis / 
Summertime Actinic lichenoid eruption / Lichenoid melanodermatosis).  
 This is generally seen in children or young adults living in tropical 
countries. Lesions occur over the sun-exposed areas (usually face), as 
well–defined annular or discoid patches, with a deeply hyperpigmented 
center surrounded by a hypopigmented zone.  
(vi) Guttate Lichen Planus  
Lesions are discrete, widely scattered, ranging from 1-2 mm to 1 cm.   
 
(vii) Follicular Lichen Planus (Lichen planopilaris / Lichen planus 
follicularis / Lichen planus peripilaris / Lichen planus acuminatus)  
 Individual keratotic follicular papules are seen predominantly over 
the scalp. It may also involve the trunk, medial aspect of the proximal 
extremities and may occur alone or in association with other forms of 
lichen planus. Cicatricial alopecia may develop over the scalp.   
viii) Erosive / Ulcerative lichen planus  
    Here, chronic painful ulcerations develop over the feet leading to 
atrophic scarring & permanent loss of nails.   
SITE OF INVOLVEMENT  
(i)  LP involving the mucous membranes: Lichen planus can affect the 
mucosa of the mouth, vagina, oesophagus, conjunctiva, urethra, anus, 
nose & larynx. Lesions confined to the mouth comprise 15% of all cases 
25
. Different types include reticulate, atrophic, erosive, papular, ulcerative 
& bullous forms.  
 In males, genitalia is involved in 25% of cases & glans penis is the 
most common site followed by penile shaft & scrotum1. In females, 
genital involvement consists of leukoplakia or erythroplakia , sometimes 
with erosions and sometimes as a generalized desquamative vaginitis. 
The association of erosive LP of the vulva & vagina with desquamative 
gingivitis is called as the vulvovaginal gingival syndrome26. 
ii) Lichen Planus of the Nails: Nail involvement occurs in 10–15% of 
patients27.Lichen planus can affect both the matrix & the nailbed. Nail 
matrix involvement results in thinning, longitudinal ridging, 
onychorrhexis, fissuring, trachyonychia, dorsal pterigium formation 
(classical finding of LP).  Lichen planus of the nailbed may give rise to 
longitudinal melanonychia28, hyperpigmentation, subungual 
hyperkeratosis and onycholysis.  
 ‘Pup tent’ sign is due to papules on the nail bed which lift the nail 
plate resulting in longitudinal splitting of the nail plate. Pterigium results 
from a focal destruction of the nail matrix with subsequent scar formation 
& attachment of proximal nail fold to the nail plate.  
iii) LP of the palms & soles: They lack the characteristic shape & colour 
and are firm, yellow papules occurring in broad sheets or as punctuate 
keratosis29. Itching may be absent. Vesicle – like papules30 have also been 
recorded. Ulceration can occur especially over the soles.  
iv) Inverse lichen planus: This consists of reddish brown, discrete 
papules & nodules distributed over the axillae, infra–mammary areas, 
groins and antecubital & popliteal areas.  
SPECIAL FORMS OF LICHEN PLANUS  
(i) Lichen planus pemphigoides: Lichen planus is acute, generalized and 
is followed by sudden appearance of large bullae in both involved and 
involved skin.  
(ii) LP / LE Overlap syndrome: It is a rare variant, with lesions that 
share features of lichen planus and lupus erythematosus. Atrophic plaques 
and patches with hypopigmentation and red to blue–violet colour with 
telangectasia & scaling are characteristic and are most common over the 
extremities.  
OTHER VARIANTS  
(i) Perforating Lichen Planus: Hanau & Sengel31 have described a 
perforating variant of lichen planus over the buttocks & volar surfaces of 
the wrist which showed transepidermal elimination of colloid bodies on 
histopathology.  
 (ii) Exfoliative Variant: Lichen planus lesions involve more than 90% 
of the body with increased scaling.  
(iii) Lichen Planus “Invisible De Gougerot”1: Here, only pruritus is 
present and lesions are not visible under naked eye, but become apparent 
with woods lamp examination. Biopsy shows lichenoid histology.  
ASSOCIATED CONDITIONS  
a) Autoimmune disorders: Alopecia Areata, diabetes mellitus, vitiligo, 
dermatomyositis, morphea, lichen sclerosus, systemic lupus 
erythematosus, pemphigus, paraneoplastic pemphigus, thymoma, 
myasthenia gravis may be associated with lichen planus.  
b) Infections: Association of lichen planus with syphilis, hepatitis C, 
herpes simplex virus, amoebiasis, chronic bladder infections has been 
reported3. HIV has also been implicated in triggering lichen planus32. 
Several reports described lichen planus like eruptions after hepatitis–B 
vaccination33.  
c) Liver disorders: Autoimmune chronic active hepatitis, primary biliary 
cirrhosis and post viral chronic active hepatitis34 are associated with 
increased frequency of lichen planus.  
d) Miscellaneous:A high prevalence of anti-cardiolipin antibodies have 
been documented in patients with HCV associated oral lichen planus35. 
Lichen planus has occurred in patients with Castleman’s tumor36, in 
certain tattoo reactions, in areas where coexisting mercury 
hypersensitivity to the injected dye exists37. 
SYNDROMES ASSOCIATED WITH LICHEN PLANUS  
1)  Graham–Little–Piccardi–Lassueur Syndrome: triad of follicular  
LP of the skin, cicatricial alopecia of the scalp and non-scarring  
alopecia of the axillary/pubic hair.  
2) Grinspan Syndrome: oral lichen planus with diabetes mellitus and  
essential vascular hypertension. 
3) Jolly’s Syndrome : association of oral LP with diabetes  
mellitus. 
4) Vulvovaginal Gingival Syndrome of Hewitt and Pelisse  
   
COMPLICATIONS  
1) Cicatricial alopecia   
2) Permanent loss of nails  
3) Ulcerative / atrophic/ plaque forms of oral lichen planus, vulval lesions 
and hypertrophic lesions23 have a potential to develop into SCC.  
4) Cicatricial conjunctivitis38 and lacrimal canalicular obstruction39  
 
DIAGNOSIS  
The classical lesions of lichen planus present no difficulty in 
diagnosis. In lesions with varied morphology, clinical picture along with 
biopsy provides the diagnosis.  
 
HISTOPATHOLOGY40  
 The classical histopathological features of lichen planus, seen in 
fully developed LP papules are  
i) Hyperkeratosis: Compact orthokeratosis  
ii) Focal hypergranulosis: Uneven and wedge shaped thickening of 
granular layer. Wickham’s striae are caused by focal increase in thickness 
of the granular layer. 
iii) Irregular acanthosis: giving rise to saw–toothed appearance.  
iv) Hydropic degeneration of the basal cell layer  
v) Band like inflammatory infiltrate consisting of lymphocytes and 
macrophages seen in papillary dermis abutting the epidermis. 
Macrophages are seen in the upper dermis due to pigment incontinence.  
vi) Colloid bodies (Hyaline / cytoid / civatte bodies): They are found 
singly or in clumps & are transformed degenerating basal epidermal cells.  
 
Max Joseph space (Caspary Joseph space)  
       Small areas of artefactual separation between the epidermis & 
dermis, known as Max–Joseph spaces are seen41. Sometimes, extensive 
damage to the basal cells results in formation of sub-epidermal blisters 
due to massive separation. Earliest finding is the increase in langerhans 
cells42 associated with a perivascular inflammatory infiltrate. 
Oral Lichen Planus: Lesions show parakeratosis without a granular 
layer. Epithelium is atrophic & ulcerations may be seen.  
 
 
Lichen Planopilaris: Early lesions show a focally dense, band–like 
perifollicular lymphocytic infiltrate at the level of the infundibulum & 
isthumus. Vacuolar changes of the basal layer of outer root sheath and 
necrotic keratinocytes are seen. Follicular plugging is present. 
Interfollicular epidermis is spared.  
 In late lesions, there is perifollicular fibrosis and epithelial atrophy 
giving rise to a HOUR GLASS configuration.  
 
Ulcerative LP : Skin adjacent to the ulcer shows changes of established 
lichen planus.  
 
Lichen Planus Actinicus: A histologic picture comprising of  
a) a form with features comprising of classical LP, with thinning of the 
epidermis in the center of the lesions with more evidence of pigmentary 
incontinence b) an intermediate form (lichenoid melanodermatitis) with 
foci of spongiosis and parakeratosis c) a more eczematous type 43.  
 
LP / LE Overlap Syndrome: histology and immunofluroscence may 
show features of lichen planus or lupus predominantly or both may 
coexist.  
Lichen Planus Pemphigoides: Biopsies from blisters on uninvolved skin 
show subepidermal bulla with an infiltrate that is not band like and which 
contains eosinophils.  
 
ELECTRON MICROSCOPY  
 Basal keratinocytes together with desmosomes and 
hemidesmosomes show degenerative changes. Necrotic keratinocytes 
contain cell organelles such as melanosomes and mitochondria, and 
rarely, nuclear material.  
            The dermal infiltrate, which extends to the epidermis,causes 
fragmentation followed by duplication & irregular folding of the lamina 
densa. Some lymphocytes have convoluted nuclei similar to sezary cells.  
 
DIRECT IMMUNOFLUROSCENCE 
            Apoptotic keratinocytes identified by globular deposits of IgM, 
IgG & IgA, are seen in large numbers or in clusters in the lower 
epidermis surrounding the DEJ. Shaggy deposits of fibrinogen at the DEJ 
is characteristic of lichen planus .  
 In lichen planus pemphigoides, DIF of perilesional lesion shows 
IgG and C3 in linear arrangement along the basement membrane zone .In 
immunoelectron microscopy, C3 is localized to the lamina lucida as in 
bullous pemphigoid.  
 TREATMENT 
Different treatment modalities are in use for lichen planus. A large  
number of drugs have been tried topically and systemically and  
corticosteroids remain the most effective treatment. Oral anti-histamines 
are useful for alleviating pruritus. Many of the advocated treatments lack 
conclusive evidence for efficacy44 
General measures: 
Avoiding the exacerbating drugs, minimising trauma to skin and 
mucosa are recommended. For oral lichen planus, good oral hygiene 
should be maintained and dental care should be instituted. 
 
Current drugs in treatment of lichen planus: 
They can be classified into 1) Topical 2) Intralesional 3) Systemic 
Topical steroids  
Topical corticosteroids are the most commonly used drugs in the 
treatment of lichen planus. 
History: 
In 1952, Sulzberger and Whitten were the first to use 
hydrocortisone in the treatment of eczematous dermatitis. Their success 
marked a corner stone in dermatology. 
 Mechanism of Action: 
Topical corticosteroids exert their effects through direct and 
indirect mechanisms which are mediated through the Glucocorticoid 
Receptor(GCR) 
The GCR belongs to the superfamily of nuclear receptors. It is 
widely distributed in almost all cells. The receptor is found as a 
component of a heterotetrameric structure containing 2 molecules of 90 
kDa heat shock protein hsp 90,and a 59 kDa protein p59 which belongs to 
the family of immunophilins. The cellular events that take place are 
1) The corticosteroid diffuses into the target cell and binds to the 
GCR-alpha  in the cytoplasm 
2) Receptor-ligand interaction results in activation of the receptor and 
dissociation from other components of the complex. 
3) Activated receptor with the ligand translocates to the nucleus and 
interacts with the specific response elements in the genome, 
glucocorticoid response elements (GRE) which results in 
modulation of transcription of various genes resulting in diverse 
cellular effects. 
4) The metabolic effects are brought about by transcription and the 
anti-inflammatory effects are brought about by trans-repression. It 
may inhibit directly or indirectly the activity of other transcription 
factors including NF- κB,AP-1,NFAT. 
 The effects are 
i) Anti-inflammatory 
a)  Direct effects: 
       1)  Stabilisation of lysosomal membranes and cell membranes 
       2)  Inhibition of mast cell stimulation by IgE 
       3)  Inhibition of release of histamine and other mast cell mediators 
 b)  GCR mediated effects (delayed) 
Induction of anti-inflammatory proteins – lipocortin, vasocortin               
 and vasoregulin 
Lipocortins inhibit phospholipase A2 and block release of      
 arachidonic acid and PAF from cell membranes preventing 
 formation of prostaglandins 
  Vasocortin and vasoregulin decrease vascular permeability. 
 ii)
 
Immunosupressive: 
a) Polymorphonuclear leucocytes: 
  Decreased adherence to the vascular endothelium, decreased 
migration to sites of inflammation, decreased phagocytosis 
b) Monocytes: 
          Decreased chemotaxis and decreased fungicidal activity 
c)  Lymphocytes: 
  Decreased antibody dependant cellular cytotoxicity and NK cell        
activity 
d)  Langerhans cells: 
1)  Superpotent TCS: loss of cells expressing Langerhans cell 
markers(CD1a). 
2)  Moderate potency steroids: decreased expression of Fc receptor, 
C3b receptor, and HLA DR positivity,but no alteration in CD1a 
antigen expression.  
iii) Vasoconstrictive effects: 
1.  Potentiation of vascular response to catecholamines 
2. Reduction of vascular smooth muscle sensitivity to histamine and     
    bradykinin 
iv )Anti-proliferative effects: 
1. Epidermis: reduction of mitotic activity in the epidermis leading to 
reduction of stratum corneum thickness, granular layer45, flattening of the 
basal cell layer, inhibition of pigment production by the melanocytes. 
2. Dermis: 
 Early atrophy: results from the reduction in dermal volume due to 
reduced water content and loss of glycosaminoglycans, hypoactive 
fibroblasts 
 Late atrophy: results from the abnormal aggregation and reduction 
of collagen and elastic fibres. Dermal vessels become fragile due to loss 
of fibrous and ground substance support. 
Potency ranking of topical corticosteroids 
 The ability of a given corticosteroid agent to cause vasoconstriction 
usually correlates with its anti inflammatory potency, and thus 
vasoconstrictor assays are used to predict the activity of an agent. The 
most commonly used test is the Stoughton vasoconstriction assay. 
Topical corticosteroids have been divided into seven classes based on 
their potency, from super potent steroids in class 1 to least potent in class 
7(American classification). 
Adverse Effects: 
 Local as well as systemic adverse effects have been documented 
with the use of topical corticosteroids under normal conditions, 99 % of 
the applied topical steroid is removed from the skin and only 1% is 
therapeutically active. Cutaneous adverse effects can result from the 
small percentage of percutaneously absorbed corticosteroid or from its 
transient presence on the skin.  
Local Adverse Effects: 
 The most common local adverse effect of topical corticosteroids is 
atrophy46. This results in shiny wrinkled fragile skin, prominent 
vasculature, stellate pseudoscars, purpura, easy bruising, ulceration and 
striae. Atrophy of the epidermis maybe seen within two weeks of daily 
use of super potent topical corticosteroids without occlusion47 or within 
one week with occlusion48. 
 The other adverse effects seen with usage of topical corticosteroids 
are impaired wound healing, contact dermatitis, facial hypertrichosis, 
folliculitis, miliaria, increased susceptibility to bacterial, fungal and viral 
infections (crusted scabies, tinea incognito, infantile gluteal granuloma), 
perioral dermatitis, rosacea, acneiform eruption, steroid rebound, 
glaucoma and cataracts (when used around the eyes) and tachyphylaxis. 
Systemic Adverse Effects: 
 Topical corticosteroids can be absorbed percutaneously in 
significant quantities to cause systemic adverse effects. These include 
suppression of the hypothalamic-pituitary-adrenal axis, Cushing’s 
syndrome, hyperglycemia, intracranial hypertension, growth retardation 
in children, reduced bone mineral density, edema, hypocalcemia, 
hypertension, cataract formation, glaucoma development and peptic ulcer.  
Contra Indications: 
1. Absolute – History of hypersensitivity to the topical 
corticosteroid or  a component of the vehicle. 
2. Relative – Untreated local bacterial, fungal, viral or 
mycobacterial infection, infestation and ulceration. 
Dosing Regimen: 
 As a working rule, not more than 45gm/week of potent topical 
corticosteroids or 100gm/week or moderately potent corticosteroid should 
be applied if systemic absorption is to be avoided. 
Usage in Pregnancy: 
              These are pregnancy category C drugs. Hence, caution is to be 
exercised when used in pregnancy. It is not known whether they are 
secreted in breast milk and they are never to be used on the breasts before 
breast feeding.  
 
 Halobetasol is a superpotent synthetic topical corticosteroid and 
has marked anti-inflammatory and anti-pruritic effects. Its chemical 
structure is: 21-chloro-6 alpha,9-difluro-11 beta,17-dihydroxy-16 beta-
methylpregna-1,4-diene-3,20-dione 17 propionate. Treatment beyond two 
weeks is not recommended, and total dosage should not exceed 
50mg/week because of the potential to suppress the HPA axis. Use in 
children <12years is not recommended.  It is contraindicated in patients 
with sensitivity to the test medications. 
 
Use in Lichen planus: 
 Although topical and intralesional steroids are the first line 
treatment, their use has been based on anecdotal reports rather than 
controlled clinical trials49. 
 Potent topical steroids (Fluocinonide 0.05%, Clobetasol propionate 
0.05%) form the mainstay of therapy of localised lichen planus lesions. 
These are applied twice daily for two weeks. In large areas of 
involvement they can be used in a diluted form (1:4 in white soft 
paraffin)50.  
 In treatment of oral lesions with triamcinolone, use of occlusive 
materials like Orobase provides protection and sustained tissue contact 
with the glucocorticoid as well as alleviates the discomfort of oral lesions. 
0.1%fluocinolone acetonide and 0.05% Clobetasol propionate in Orobase 
showed good results. Application is 4–6 times per day51. Corticosteroid 
lozenges, betamethasone mouth washes 0.5mg 3-4 times daily52 are 
beneficial. 
 
Vulvovaginal lichen planus can be treated with vaginal 
hydrocortisone suppositories53. Sialistic prosthetic devices have been 
used to increase the delivery of topical corticosteroids to mucosal 
surfaces like vagina and buccal mucosa54. 
 Hypertrophic lesions and palmoplantar lesions benefit from the use 
of potent topical corticosteroids under occlusion. 
  
Rubbing a potent topical corticosteroid on the nail folds maybe 
helpful in the active stage of the disease55. Topical anaesthetics maybe 
combined with topical corticosteroids for relief of pain in mucosal 
lesions.   
 
Topical Calcineurin inhibitors: 
Topical calcineurin inhibitors like Tacrolimus, Pimecrolimus, 
Cyclosporine have been used to treat lichen planus. These are  non-
steroidal agents that act through immunological pathways to modify  
the immune and inflammatory responses in skin. 
 
Tacrolimus: 
       Tacrolimus is a macrolactam class of cytokine inhibitor and is anti- 
Inflammatory56. 
 
It was first isolated from a soil fungus Streptomyces tsukubaensis  
near Tsukuba, Japan. It was known earlier as FK506, its experimental  
name.  Its new name is derived from Tsukuba, the location of its  
discovery, macrolide, its chemical class, and immune suppressant, its  
primary activity in humans57. 
  Mechanism of action: Tacrolimus is an inhibitor of the phosphatase,  
calcineurin . 
T-lymphocyte activation occurs through the following steps: 
1)  Interaction of co-stimulatory ligands on antigen-presenting cells  
     with T-cell receptors 
2)  Increase in levels of free calcium within the cell 
3)  Binding of calcium to calmodulin,which in turn activates  
    calcineurin [Calcium/Calmodulin dependant serine/threonine  
     phosphatase] 
4)   Dephosphorylation of cytoplasmic subunit of the nuclear factor of  
     activated T cells[NFAT] by calcineurin         
5)   Translocation of the dephosphorylated subunit to the nucleus,  
     formation of a complex and transcription of cytokines like IL-2,  
     IL-3,IL-4,IL-12,TNF-alpha,IFN-gamma58 
Tacrolimus binds to the FK-506 binding protein [FKBP], forming  
complexes that inhibit calcineurin , thus preventing its  dephosphorylation 
activity and production of cytokines necessary for  T cell activation.  
Effects include 
1) inhibition of T cell proliferation 
2) inhibition of production of cytokines IL-2,IL-3,IL-4,IL-12,TNF-
 alpha, IFN-gamma 
3) inhibition of mast cell adhesion 
4) inhibition of release of mediators from mast cells and basophils 
5) down regulation of  the expression of IL-8 receptor and FcεRI on 
 Langerhans cells59 
6)  Acts on keratinocytes to increase stem cell factor release ,causing 
proliferation of melanocytes and melanoblasts60 in vitiligo 
7) Also influences nerve fiber function by binding to a receptor on 
small unmyelinated sensory nerve fibres, the TRPV161 [ Transient 
Receptor Potential cation channel subfamily V member 1, the 
capsaicin receptor] Activation of this receptor results in 
transmission of burning pain and itch. This explains the initial 
burning and pruritus on application. Continuous stimulation of the 
receptor causes it to be finally desensitised. 
        Tacrolimus is effective even when applied topically by affecting 
local immunosupression at areas of application. Tacrolimus is 10-100 
times more potent than cyclosporine in inhibiting T cell activation and its 
ability to penetrate the skin is greater. Moreover, topical formulation 
delivers the active ingredient directly to the inflamed sites in the skin 
while minimising the systemic exposure of tacrolimus52. Tacrolimus has 
been found to cause significantly less atrophy than topical 
corticosteroids54 as it does not alter the collagen synthesis even under 
occlusion. 
Formulations: 
Both 0.03% and 0.1% are available.0.1% has been shown to be 
more effective in treating lesions of erosive oral lichen planus63,erosive 
lichen planus of  the  sole64 ,vulvovaginal lichen planus65 as damaged skin 
has sevenfold higher rate of absorption of tacrolimus. There has been a 
case report on the successful use of topical tacrolimus in cutaneous lichen 
planus66 and also in nail lichen planus67. 
Adverse effects: 
             The major adverse effect is local irritation mainly burning and 
stinging at the site of application. Allergic contact dermatitis, rosacea like 
granulomatous reaction, increased incidence of skin infections have also 
been reported. There is theoretical risk of increased malignancy in 
patients treated with tacrolimus. 
Contraindications include pregnancy, infected lesions and exposure 
to sunlight. Vaccinations cannot be given during treatment and for 28 
days after that. Safety has not been evaluated in children younger than 2 
years and in nursing mothers  
Topical cyclosporine 5 ml of 100 mg/ml solution 3 times a day can 
be used as mouthwash [swish for 5 minutes and spit ] or manually by 
local massage68.  
 
Topical Retinoids: 
 
Topical retinoids like Retinaldehyde70, Isotretinoin gel (0.1%)69,  
tazarotene71, etretinate72 have been tried in treatment of oral lichen  
planus. 
 
Others:  
Topical calcipotriol is of limited use in cutaneous lichen planus73 
.Topical Aloe Vera gel74, Imiquimod 5% cream75, topical tetracycline76 
have also been tried in oral lichen planus. 
 
Intralesional steroids: 
Intralesional triamcinolone acetonide (5 to 10 mg/dL) is effective 
in treating oral and cutaneous lichen planus. For hypertrophic lichen 
planus, 10-20 mg/dL may be required once in 3-4 weeks. It may also be 
used for lichen planus of the nail with injection every 4 weeks. 
Regression occurs within 3-4 months. Side-effects include atrophy, 
localised hypopigmentation or depigmentation and telangectasia 
 
 
SYSTEMIC THERAPY: 
Systemic steroids: 
Indications: 
1) generalised eruptive lichen planus 
2) progressive nail lichen planus 
3) active stage of follicular lichen planus of scalp causing alopecia 
4) erosive oral or genital lichen planus 
 Usually, prednisolone in the dose of 0.5-1 mg/kg body weight in a 
gradually tapering dose for 6 weeks is helpful. Symptoms are alleviated 
and patients experiencing a flare have marked response. However, relapse  
may occur with quick tapering of therapy. Long term continuation is 
contraindicated due to high risk of complications. 
Adrenocorticotrophic hormone (ACTH])or tetracosactin may also 
be used50 
Pulse therapy: 
Synder et al77 described use of pulse therapy with methylprednisolone 1 g 
daily for 3 days each month for 3 months. 
 
Systemic Retinoids: 
Their anti-inflammatory property has been used in treatment of 
lichen planus. Acitretin, used in dosages of 30 mg/day for 8 weeks 
showed marked improvement78.Oral tretinoin used at 10-30 mg/day79, 
low dose etretinate80 10-20 mg/day for 4-6 months have also shown 
improvement. Isotretinoin in the dose of 20-40 mg/day has also been 
tried81.  
 
Immunosuppressive agents: 
1) Systemic cyclosporine has been tried for recalcitrant lichen planus, 
severe oral erosive lichen planus in the dose of 1-6 mg/ kg/ day82.It 
is also a therapeutic option for severe nail lichen planus55. Side 
effects like renal toxicity, hypertension and relapse after 
discontinuation of cyclosporine limit its use to only severe cases. 
2) Azathioprine83 is useful in recalcitrant, generalised cutaneous 
lichen planus. 
3) Methotrexate84, Mycophenolate moefitil85, Cyclophosphamide86 
have also been tried in refractory cases 
Others: 
i) Dapsone in doses of 100-200 mg / day 87 has been found effective 
in patients with cutaneous and oral disease. 
ii) Antimalarials like hydroxychloroquine at doses of 200-400 mg/day 
is helpful in actinic and oral lichen planus88. 
iii) Thalidomide can be tried in recalcitrant cases89, treatment of lichen 
planopilaris of scalp90. 
iv) Metronidazole can be tried in cutaneous and severe oral lichen 
planus91. 
v) Antifungals: Griseofulvin92 has been found to be effective in 
treatment of lichen planus. Itraconazole93 has also been tried. 
vi) Combination therapy with tetracycline or doxycycline  and 
nicotinamide has been reported as useful in treatment of lichen 
planus pemphigoides94. 
vii) Low molecular weight heparin in doses of 3 mg weekly 
subcutaneous injections has been found to be effective in cutaneous 
and reticulated oral lesions95. 
viii) Interferon α2b has been administered for treatment of generalised 
lichen planus though this response modifier has also been 
implicated in the development or exacerbation of lichen planus96. 
ix) Others like phenytoin97,sulfasalazine98 ,basiliximab99, 
efalizumab100,alefacept101 have also been tried in the treatment of 
lichen planus. 
 
Photochemotherapy : 
i) PUVA can be used alone or in combination with steroids to hasten 
the response102 in generalised cutaneous lichen planus. RePUVA 
can also be tried though it is found to produce 
hyperpigmentation103.     
ii) UVA1 phototherapy may help in protracted lichen planus104. 
iii) NB UVB is useful in treatment of widespread cutaneous lichen 
 planus105.  
 
 Lasers: 
i) Excimer laser was found to be very effective in one study for the 
treatment of erosive oral lichen planus106. 
ii) Nd YAG, Carbon dioxide lasers have also been used to treat oral 
lichen planus107. 
 
Photodynamic therapy: 
 Resistant and recurrent cases of oral lichen planus have been 
treated with photodynamic therapy mediated methylene blue(MB-
PDT)108. 
 
Extracorporeal photopheresis: 
It has been found to be effective in treatment of erosive oral lichen  
planus109 but concomitant topical treatment is required.  
 
 
 
Follow up: 
 Lichen planus runs a chronic course , over months to years. 
Relapse occurs in 15-20% of cases1.Generalised eruptive lichen planus 
and erosive lichen planus are particularly prone to relapse and chronicity. 
Patients with variants at risk of malignant transformation should be 
regularly followed up and repetitive biopsies may be needed to rule out 
malignancy. 
Monitoring of therapeutic response can be done by certain 
biochemical parameters. Response in oral lichen planus can be monitored 
by salivary analysis of NFĸB dependant cytokines (TNF-alpha, IL- 12, 
IL-6, IL-8) but its value is signicantly reduced by treatment with 
dexamethasone 110.Estimation of serum ACE activity , though non-
specific, may be a good parameter for assessing the therapeutic 
response111.  
        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                    AIM OF THE STUDY 
  
 
 
To compare the efficacy of topical halobetasol and topical tacrolimus in  
 
the treatment of  localised cutaneous lichen  planus lesions. 
 
 
Agents compared: 
 
1) 0.05% Halobetasol propionate ointment 
 
     2) 0.1% Tacrolimus ointment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
             MATERIALS AND METHODS 
 
 
Study design: prospective, randomised, open label clinical trial.  
 
Study subjects: Sixty subjects with cutaneous lichen planus. 
 
Study duration: August 2008 to August 2010. 
 
Study setting: Out-patient department of the Department of  
 
                         Dermatology, Government General Hospital, Chennai. 
 
Ethical committee: Approved 
  
 
Inclusion Criteria: 
 
1) Subjects of either sex with biopsy confirmed symptomatic  
 
     localised ( < 10%  of body surface area) lichen planus lesions. 
 
2) Subjects who have not been on any form of therapy for atleast a  
 
     month prior to their enrolment. 
 
 
Exclusion Criteria: 
 
1) Lichen planus with facial/ mucosal involvement. 
 
2) Use of drugs known to produce lichenoid reaction. 
 
3) Pregnant/ lactating women. 
 
4) Children < 12 years of age. 
 
5) Subjects with  prior history of hypersensitivity to any of the  
 
     components of the test medications. 
 
 
Treatment protocol and Methodology: 
 
 
Subjects attending the out-patient department of the Department of  
 
Dermatology, Government General Hospital, Chennai who met the  
 
above mentioned inclusion criteria were offered to participate in the  
 
study. Those who elected to participate in the study signed an  
 
informed consent.   
 
 
At baseline: 
 
 
Clinical profile: 
 
     Demographic data such as age, sex, occupation, marital status and  
 
     were taken. 
 
Severity of itching, duration and progression of lesions,  family 
history of lichen planus, past and  present history of topical and 
systemic treatment for lichen planus, h/o intake of drugs known to 
induce a lichenoid reaction, h/o contact with photodevelopers,          
h/o recent vaccination for hepatitis B were noted. 
History of diabetes, hypertension, jaundice, thyroid disorders,radiation 
therapy to the site of involvement, recent mental stress,anxiety, 
alopecia areata, vitiligo, morphea, dermatomyositis, SLE, pemphigus 
were asked for. 
             Patients were subjected to general and systemic examination. 
Blood pressure was noted. Thorough dermatological examination was 
done and other dermatological lesions, site of involvement of lichen 
planus, morphology of lesions, number of lesions, koebners 
phenomenon  were recorded. Blood group was noted. 
 
Blood glucose, complete blood count, hepatic and renal chemistry,  
 
VDRL, rapid tests for HIV were done at baseline. Photography was  
 
taken at baseline. Diagnosis was arrived based on clinical grounds and  
 
biopsy. 
 
 
 
 
Study: 
 
• Patients were randomly allocated into the 2 groups. 
 
• The study was divided into 2 phases. 
 
      Phase 1 consisted of topical treatment for 2 weeks. 
 
      Phase 2 was a two month follow-up period without any therapy 
 
 
Phase 1: 
         
    
 
 
  Group 1:  
 
  Patients in this group received 0.05% halobetasol propionate 
ointment. The patients were advised to apply the ointment only over 
the lesions twice daily for a period of 2 weeks or until the lesions 
cleared, whichever was earlier & to avoid using the medication over 
ulcerated areas. Patients were instructed to refrain from using other 
topical or systemic medication for lichen planus for the above period. 
They were asked to come at weekly intervals for 2 weeks for 
assessment. The patients were asked to return all unused medication at 
each visit and the quantity of returned medication was used to assess 
patient compliance. Patient Visual Analogue Scale for pruritus [VAS 
consisted of a horizontal line marked 0(= no itching) to 10(= more 
severe itching)] and Clinician VAS for thickness [0= flat to 10= highly 
raised ] were marked & photographs were taken at each visit. They 
were instructed about the side effects of therapy like 
hypopigmentation, atrophy, impaired wound healing, folliculitis, 
increased infections at the application site and to report them if any. 
Signs of the adverse effects like hypopigmentation, atrophy, purpura, 
telangectasia, folliculitis, miliaria, acneiform eruptions were also 
looked for at each visit. 
 Group 2: 
Patients in this group received 0.1% tacrolimus ointment & were 
advised to apply the ointment only over the lesions twice daily for a 
period of 2 weeks or until the lesions cleared, whichever was earlier. 
They were also asked to refrain from using other topical or systemic 
medication for lichen planus for the above period. The patients were 
asked to return all unused medication at each visit and the quantity of 
returned medication was used to assess patient compliance. 
Assessment was done at weekly intervals. Patient Visual Analogue 
Scale for pruritus and Clinician VAS for thickness were marked and 
photographs were taken at each visit. They were instructed about the 
side effects of therapy like burning, stinging & increased infections at 
the site of application and were asked to report them, if any, at each 
visit. Signs of the adverse effects were also looked for at each visit.  
     
Evaluation of response: 
  
The symptomatology score was obtained using the patient’s Visual  
 
Analogue Scale & the signs were assessed based on the  
 
clinician’s VAS score for thickness at each visit and a decrease, an  
 
increase or no change in the score meant response, worsening or  
 
persistence of the condition respectively. 
            Improvement ratio was calculated as follows. 
 
Improvement ratio =Pre-treatment total score  -  
 
                                                        post-treatment total score 
                                       ------------------------------------------------- * 100 
 
                                                  Post- treatment total score 
 
  
Based on the improvement ratio, physician’s clinical evaluation of the  
 
change in disease status was made according to the following criteria: 
 
 
1) cleared :  improvement  ratio = 100 (except for post-inflammatory  
 
hyperpigmentation) 
 
2) marked improvement : improvement  ratio = 75 to <100  
 
3) moderate improvement : improvement  ratio =  50 to < 75 
 
4) slight improvement : improvement  ratio =  <  50  
 
5) no change = no detectable improvement from pre-treatment  
 
 evaluation 
 
6) Exacerbation = flare of sites monitored 
 
 
Phase 2: 
 
 
Follow-up: 
 
Follow-up of the two groups was done at 4 weeks and 8 weeks 
after the cessation of therapy. Patients were asked not to use any 
concurrent medication for the lesions & the following were noted. 
i) occurrence of new lesions ii) relapse of lesions at the same site iii) 
exacerbation of the existing lesions iv) no change in the existing lesions. 
 
 
 
 
 
Statistical Analysis: 
 
1. In each study group, mean values for pruritus and thickness scores 
were calculated and compared using Non-parametric repeated 
measures ANOVA test (Friedman test). 
2. To look for significant association between the response and the 
sex, age, duration, site of involvement and the blood group, 
Fisher’s Exact test was used. 
3. A p value of < 0.05 was considered statistically significant. 
              
 
 
 
 
 
OBSERVATIONS 
 
            The following observations were made in the present study. 
Among the 60 patients under study, 31 were males and 29 were females. 
They were in the age group ranging from 13 years to 69 years with mean 
age of 35.4 years. The duration of lichen planus ranged from 2 weeks to 2 
years with mean duration of 5.5 months. Family history of lichen planus 
was positive in 6.7% of patients, all had onset < 20 years of age. History 
of previous topical application was present in 15% of patients. The time 
interval between the last and the present therapy ranged from 1 to 6 
months. None of them had had systemic treatment.  
 
 
1) Sex Distribution 
          Sex     No of patients   Percentage 
         Male             31      52% 
         Female             29      48% 
 
 
 
 
2) Age distribution   
Age 
Males 
(n=31) 
% 
Females 
(n=29) 
% 
10-20 Years 6 19 5 17 
20-30 Years 7 23 6 21 
30-40 Years 8 26 8 27 
40-50 Years 5 16 4 14 
50-60 Years 4 13 2 7 
> 60 Years 1 3 4 14 
 
 
 
 
 
 
3) Duration of lesions: 
 
Duration Males 
n=31 
Females 
n=29 
< 1 month 6 9 
1 month – 6 months 14 16 
6 months – 12 months 7 2 
> 12 months 4 2 
 
 
4) Blood group distribution 
O was the predominant blood group followed by A in this study.  
Blood Group Males 
n=31 % 
Females 
n=29 % 
O+ve 11 35 10 35 
O-ve 3 10 2 7 
A+ve 8 26 9 31 
A-ve 0 0 3 10 
B+ve 6 19 2 7 
B-ve 1 3 0 0 
AB+ve 2 7 3 10 
AB-ve 0 0 0 0 
  
5) Type of lesions 
 
The majority (62%) presented with classical lichen planus; pigmentation  
was seen in all patients and a large proportion had  the typical features of  
violaceous colouring, scaling and Wickham’s striae. All patients had 
pruritus. 
  
 
Type Of Lesion 
Males 
n=31 
% 
Females 
n=29 
% 
Classical 17 55 20 69 
Hypertrophic 9 29 6 21 
Linear 3 10 3 10 
LP of the palms and soles 2 6 0 0 
6) Site of involvement 
Lower limb (53.5%) was the most common site of involvement. 
 
7) Autoimmune disorders associated 
Other autoimmune disorders associated were vitiligo vulgaris, diabetes 
mellitus and alopecia areata. 
   
 
 
 
 
 
 
Site Males 
n=31 
% Females 
n=29 
% 
Upper Limbs 11 35 11 38 
Trunk 1 3 3 10 
Lower Limbs 17 55 15 52 
Palms and Soles 2 7 0 0 
Diseases 
Male 
n=31 
Female 
n=29 
Vitiligo Vulgaris 3 1 
Diabetes Mellitus 2 5 
Alopecia Areata 1 0 
 8)Demographics  
 
The baseline demographics of the two study groups were comparable 
with respect to sex distribution, mean age, mean duration of lesions, type 
of lesions, site of involvement and blood group. 
   
Variables Group 1 
Halobetasol 
Group 2 
Tacrolimus 
No of patients 30 30 
Gender (M/F) 16/14 15/15 
Mean duration  
of lesions 
166 days 163 days 
Mean Age 34.5 years 36.2 years 
Type of lesions 
Classical  
Hypertrophic 
Linear 
LP   
of palms/soles 
 
18 
9 
2 
1 
 
19 
6 
4 
1 
 Site of involvement 
Upper limb 
Lower limb 
Trunk 
Palms and Soles 
 
10 
17 
2 
1 
 
12 
15 
2 
1 
Blood group 
O+VE 
O-VE 
A+VE 
A-VE 
B+VE 
B-VE 
AB+VE 
AB-VE 
 
10 
3 
8 
2 
3 
1 
3 
0 
 
11 
2 
9 
1 
5 
0 
2 
0 
            
 
 
 
 
 
THERAPEUTIC RESPONSE: 
Pruritus-Response: 
The patient Visual Analogue Scale scores for pruritus  
1) in the halobetasol group in weeks 1 and 2 dropped from a mean of 6.13 
at baseline to 3.6 at day 7 and 1.5 at day 14 which were both statistically 
significant(p<0.01).  
 2) in the tacrolimus group, the mean had dropped from 6.13 to 4.63 at 
day 7(statistically significant, p<0.01) and 2.63 at day 14(statistically 
significant, p<0.01) 
            The difference between the mean scores of pruritus between the  
 
two groups had a p value of 0.018(statistically significant) at the end of 2  
 
weeks.  
 
Patient VAS score at baseline (0 weeks), 1 & 2 weeks with halobetasol 
 
Pruritus 0 
Week 
1 
Week 
2 
Weeks 
Mean 6.13 3.6 1.5 
p value  < 0.01 
 
<0.01 
Patient VAS score at baseline (0 weeks), 1 & 2 weeks with tacrolimus 
 
 
Pruritus 0 Week 1 Week 2 Weeks 
Mean 6.13 4.63 2.63 
p value  < 0.01 <0.01 
  
 
 
Treatment differences from VAS assessments between Halobetasol 
and Tacrolimus at 2 weeks 
 
Pruritus Halobetasol Tacrolimus p value 
Mean 1.5 2.63 0.018 
 
 
 
Thickness – Response: 
The physician Visual Analogue Scale scores for thickness 
1) in the halobetasol group dropped from a mean of 6.4 at baseline to 
4.03 at day 7 and 2.33 at day 14 which were both statistically 
significant.(p value <0.01) 
2) In the tacrolimus group, the mean dropped from 6.36 at baseline to 
5.43 at day 7( p value >0.05,not statistically significant) and 4.26 at 
day 14(p value < 0.01,statistically significant) 
 
 The difference between the two groups in the mean scores of 
thickness had a p value of 0.03 at the end of 1 week and 0.0074 at the 
end of two weeks which were both statistically significant. 
Physician VAS score at baseline (0 weeks), 1 & 2 weeks with 
halobetasol 
 
 
Thickness 0 Week 1 Week 2 Weeks 
Mean 6.4 4.03 2.33 
p  < 0.01 <0.01 
 
 
Physician VAS score at baseline (0 weeks), 1 & 2 weeks with 
tacrolimus 
 
Thickness 0 Week 1 Week 2 Weeks 
Mean 6.36 5.43 4.26 
p  >0.05 <0.01 
 
 
Treatment differences obtained from VAS assessments between 
Halobetasol and Tacrolimus at 1 week 
 
Thickness Halobetasol Tacrolimus p Value 
Mean 4.03 5.43 0.03 
 
 
Treatment differences obtained from VAS assessments between 
Halobetasol and Tacrolimus at 2 weeks 
 
Thickness Halobetasol Tacrolimus p Value 
Mean 2.33 4.2 0.0074 
 
 
 
7th day of clinical assessment 
 
1) In the halobetasol group, 1 patient cleared, 7 showed marked 
improvement, 8 showed slight improvement and 2 had no change 
in lesions.  Majority (40%) were in the moderate improvement 
category. 
2) In the tacrolimus group, no patients cleared or showed marked 
improvement, majority of patients (46.6%) were in the slight 
improvement category, 7 had moderate improvement and 9 had no 
change in the lesions. 
 
14th day of clinical assessment 
 
1) In the halobetasol group, all patients showed improvement of 
whom 10 cleared, 8 had marked improvement, 8 had moderate 
improvement and 4 showed slight improvement. 
2) In the tacrolimus group, 2 cleared, 11 had slight improvement, 5  
 
 had marked & 5 had moderate improvement, 7 had no change.  
 
 Exacerbation was not seen in any patient.  
 
The difference between the two groups in clearance rates showed a  
 
statistically significant difference at the end of 2 weeks with a p value  
 of 0.021. 
 
 
Clinician assessment of change in disease status 
 
 
 DAY 7 DAY 14 
 Halobetasol Tacrolimus Halobetasol Tacrolimus 
Cleared 1(3.3%) - 10(33.3%) 2(6.67%) 
Marked 
Improvement 
7(23.3%) - 8(26.7%) 5(16.6%) 
Moderate 
Improvement 
12(40%) 7(23.3%) 8(26.7%) 5(16.6%) 
Slight 
Improvement 
8(26.6%) 14(46.6%) 4(13.3%) 11(36.7%) 
No Change 2(6.7%) 9(30%) - 7(23.3%) 
Exacerbation - - - - 
 
 
 
 
Follow-up: 
       1) At week 4 of follow-up, 36.6% of patients in the halobetasol group 
and 43.3% of patients in the tacrolimus group developed new lesions. 
Relapse of lesions were found in 5(16.6%) of halobetasol and 1 (3.33%) 
of tacrolimus group. No change in existing lesions was found in 23.3% of 
halobetasol and 33.3 % of tacrolimus group. 
     2) At week 8 of follow-up, number of new lesions increased in both  
 
the groups with 46.6% of patients in the halobetasol group and 53.3%    
 
of patients in the tacrolimus group having new lesions, with no significant  
 
difference between the two. Significant difference was seen in  
 
the relapse of lesions, with more people in the halobetasol group  
 
experiencing relapse compared to the tacrolimus group(p=0.04 by  
 
Fisher’s exact test).  
 
 
Follow-up period 
 
 Halobetasol Tacrolimus 
 Week 4 Week 8 Week 4 Week 8 
New Lesions 11(36.6%) 14(46.6%) 13(43.3%) 16(53.3%) 
Relapse 5(16.6%) 9(30%) 1(3.33%) 2(6.67%) 
Remission 10(33.3%) 3(10%) 7(23.3%) 4(13.3%) 
No Change In 
Existing Lesions 
7(23.3%) 6(20%) 10(33.3%) 10(33.3%) 
 
 Adverse effects:  
        
 No serious adverse effects were noted. About 40% of patients in the 
tacrolimus group experienced mild burning sensation, more on the first 
week of treatment. This subsided spontaneously and no patient 
discontinued treatment. 
        In the halobetasol group, no significant side effect was noted. The 
most common adverse effect noted was the hypopigmented halo around 
the lesions, which was seen in 36% of patients. 
 
 
Assessment of response based on sex 
 
With respect to sex, no significant difference in treatment response was 
seen in both the groups. 
 
 Halobetasol Tacrolimus 
 Male Female Male Female 
Cleared 4 6 1 1 
Marked 
Improvement 
4 4 2 3 
 
 
Assessment of response based on age 
 
 
With respect to age, no significant difference was seen in the halobetasol  
 
group with respect to rate of clearance. In the tacrolimus group, clearance  
 
and marked improvement was seen in the 20-40 years age group.  
 
 
 H T H T H T H T H T H T 
 11-20 
yrs 
21-30 
yrs 
31-40 
yrs 
41-50 
yrs 
51-60 
yrs 
>60 
yrs 
Cleared 2 - 2 1 3 1 2 - - - 1 - 
Marked 
Improvement 
3 - 2 2 1 3 1 - - - 1 - 
 
 
 
Assessment of response based on site of involvement 
 
With respect to the site of involvement, there was no significant 
difference in the rate of clearance between the exposed and non-exposed  
(p = 0.3985) areas in the halobetasol group whereas in the tacrolimus 
group, good response was observed in lesions over the exposed areas  
(p = 0.02 by Fisher’s exact test). 
 
 
                        
 H T H T 
 Exposed sites Unexposed sites 
Cleared 5 2 5 - 
Marked 
Improvement 
6 5 2 - 
 
 
 
Assessment of response based on blood group 
 
With respect to the blood group, all patients in blood group O responded 
to tacrolimus, and all patients who cleared were in the O group. In the 
halobetasol group, no significant difference in clearance was seen 
between O and A groups. 
 
 
 H T H T H T H T 
 O group A group B group AB group 
Cleared 4 2 6 - - - - - 
Marked 
Improvement 
4 3 1 1 1 - 2 1 
 
 
 
 
 
 
 
 
 
Assessment of response based on duration 
 
With respect to the duration of lesions, early lesions showed a better 
response with tacrolimus. Both lesions which cleared belonged to the <1 
month category. 
 
 H T H T H T H T 
 <1 
month 
>1month-
6months 
>6 months -
1year 
>1 
year 
Cleared 4 2 4 - 1 - 1 - 
Marked 
Improvement 
3 3 3 2 2 - - - 
 
 
 
 
 
 
 
 
 
DISCUSSION 
 
           In our study, we found males and females to be equally affected 
which was consistent with the study done by Bhattacharya et al19 
          Increased prevalence of lichen planus was found in patients aged 
between 20 and 40 years of age which is lower than that described1 but 
consistent with the study by Bhattacharya et al19 
           Family history of lichen planus was found in 6.7% of patients in 
our study, all of whom had onset of lesions within 20 years of age. 
Hereditary factor in the causation of lichen planus has been documented. 
             The association of lichen planus with blood group A has been 
described20. In our study, we found an increased incidence among 
patients with blood group O followed by blood group A. 
             Studies reveal the predominance of classical type among patients 
of lichen planus19,112 
.
 Our study was consistent with them. 
          Though topical steroids are the 1st line treatment and  are 
commonly used in lichen planus, very few clinical trials on the treatment 
of cutaneous lichen planus with topical steroids are available and no 
convincing evidence of their efficacy is seen in literature.
 
           Moreover, though a case of cutaneous lichen planus reported by 
Fortina et al66 showed a dramatic response to tacrolimus, stressing that 
topical tacrolimus may be an effective therapy for cutaneous lichen 
planus, to the best of our knowledge, there is no clinical trial dedicated to 
the treatment of cutaneous lichen planus with tacrolimus, especially from 
India and no evidence of its efficacy.    
           Large and randomised trials are difficult to perform in lichen 
planus as no standardised methods exist for evaluation of the severity of 
the disease, no consensual criteria of improvement or cure and variable 
course of the disease according to the clinical form or individual. 
In our study, 
Group 1 [ Halobetasol group ] 
        Halobetasol caused a statistically significant improvement in 
pruritus and reduction in thickness within 1 week of commencement of 
therapy. The clinician assessments at the end of 1 week showed marked 
improvement and clearance of lesions in >25% of patients. At the end of 
2 weeks, marked improvement and clearance of lesions was seen in 60% 
of patients. Within 8 weeks of cessation of therapy, out of 30 patients, 9 
(30%) suffered a relapse. 
         Though adverse effects are expected to occur with the use of 
superpotent steroids, due to the shorter period of time used, there were no 
significant side effects associated with the use of halobetasol in our study 
except for hypopigmentation around the lesions. There was no significant 
difference in the rate of response with respect to age, sex or site of 
lesions. All patients showed improvement. 
Group 2 [ Tacrolimus group] 
       Patients in this group experienced a significant reduction in pruritus 
& it was statistically significant at 1 week of therapy. The clinician 
assessments at the end of the first week showed that none of the patients 
cleared or showed marked improvement .The reduction in thickness was 
also not significant at the end of 1 week. At the end of 2 weeks, 6.7% of 
patients cleared and 16.6% showed marked improvement. Although 
topical tacrolimus is effective in controlling disease, it rarely seems to 
result in complete remission within 2 weeks, probably due to slow onset 
of action.  
         There was no significant difference in the rate of response with 
respect to sex. Patients with blood group O and lesions with a shorter 
duration responded better to tacrolimus than other blood groups and those 
with long-standing lesions, it was however not statistically significant. 
 Local irritation in the form of burning was the most common adverse 
effect noted that subsided with continued treatment which is probably due 
to its action on nerve fibre function61. 
          Those patients with lesions on the exposed sites responded better 
than those on unexposed sites (p value<0.05). Silverberg et al113 
suggested that the combination of tacrolimus ointment and UV light 
might be superior to that of tacrolimus ointment alone, but that UV light 
is not necessary for the beneficial effect of tacrolimus ointment. This 
probably could explain the better response seen in the exposed parts. In 
our study, treatment of localised cutaneous lichen planus over the 
exposed parts with tacrolimus is promising. However, this study is the 
first of its kind and more robust data need to be obtained in large double-
blind controlled studies. 
    In the follow up period, at the end of 8 weeks, out of 30 patients, 
2(6.7%) patients suffered a relapse, which was lower than the halobetasol 
group. 
          In comparison, there is a statistically significant difference in the 
symptomatic improvement and clearance rates with halobetasol at the end 
of 2 weeks of therapy compared to tacrolimus ( p value <0.05 ).The 
greater reduction in thickness with halobetasol could be due to its anti-
proliferative effect47 in addition to its anti-inflammatory and 
immunosuppressive effect. Relapse rates were lower with tacrolimus 
group compared to the halobetasol group (p value< 0.05). 
         Thus, our study suggests that though halobetasol is known to be 
very effective, tacrolimus might have a role in the management of early 
lesions and as maintenance regimen for localised cutaneous lichen planus.          
The major limitation of our study is the small sample size. Hence, larger 
trials with long term follow-up are needed to prove the efficacy, safety 
and stability of response with topical tacrolimus in the treatment of 
cutaneous lichen planus.  
                              
CONCLUSION 
 
• In this study, males and females were found to be equally affected 
with lichen planus. 
• Increased prevalence was noted in the age group of 20-40 years. 
• The predominant blood group in this study was blood group O. 
• The predominant type of lichen planus was the classical type. 
 
• After 2 weeks of study period, topical halobetasol caused a 
significant reduction in symptoms (p value = 0.018) and 
clearance rates (p value=0.021) compared to tacrolimus in 
localised cutaneous lichen planus. 
 
• After 8 weeks of follow-up, topical tacrolimus resulted in lower 
relapse rates compared to halobetasol (p value = 0.04). 
 
• In the halobetasol group, there was no change in rate of 
response with respect to site of involvement, blood group or 
duration of lesions. 
 
  
• In the tacrolimus group,  
o better response was seen over the exposed parts 
compared to the non-exposed parts ( p value = 0.02) 
o Patients with blood group O and shorter duration of 
lesions responded better compared to other blood groups 
and long-standing lesions. However, the differences were 
not statistically significant. 
 
• This is the first study comparing topical halobetasol and topical 
tacrolimus head-to-head. Prospective randomized trials with 
more subjects are needed before any treatment 
recommendations can be made based on the conclusions of our 
study. 
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                                        PROFORMA 
 
            
Name:                                             Age:                       Sex: 
OP no:                                            Blood group: 
Occupation: 
Address: 
 
Presenting complaints: 
Duration: 
Onset:  sudden / insidious 
Progression:  
H/O itching :  
H/O photosensitivity:   yes / no 
H/O previous systemic or topical treatment for LP: 
H/O drug intake for DM/ HT/ TB/Epilepsy: 
H/O genital lesions: 
H/O burning sensation on taking food: 
H/O excessive hair fall: 
H/O bullous lesions: 
H/O jaundice: 
H/O loss of weight/loss of appetite: 
H/O contact with photodevelopers: 
H/O recent hepatitis B vaccination: 
H/O dental procedures: 
H/O X-ray/ radiation exposure : 
H/O chronic bladder infections: 
H/O amoebiasis: 
H/O suggestive of vitiligo/ morphea/  
myasthenia gravis/SLE/dermatomyositis: 
H/O recent mental stress/ anxiety/ depression: 
Past history: 
H/O similar episodes in the past & treatment taken: 
H/O DM/ HT/ TB/ Malaria/ Epilepsy: 
Personal history: 
Married / Unmarried 
No of children: 
Smoker / Alcoholic 
Tobacco usage: 
H/O exposure to STD: 
Family history: 
General examination: 
Anemia / Cyanosis / Jaundice / Clubbing / Pedal edema / 
Lymphadenopathy 
Pulse:                              CVS:                            RS: 
BP:                                  P/A:                             CNS: 
Dermatological examination: 
Site of involvement: 
Distribution: 
No of lesions: 
Morphological type: 
Koebnerisation: 
Exposed / Unexposed site: 
Mucous membrane ( oral/ genital): 
Palms and soles: 
Nails: 
Associated skin lesions: 
Investigations: 
Blood: 
1) Complete Blood Count 
2) Blood sugar 
3) Liver Function Tests 
4) Renal Function Tests 
5) Blood grouping 
6) VDRL 
7) HIV 
Urine routine: 
Skin Biopsy: 
Treatment: 
Evaluation of response: 
 0 WEEK: 
 
1) Patient VAS for pruritus: 
  0         1        2        3        4        5         6        7        8         9       10 
No itch                                                                                         severe itch 
 
2) Physician VAS for thickness: 
    0         1        2        3        4        5         6        7        8         9       10 
Flat                                                                                         highly raised 
WEEK 1: 
 
1) Patient VAS for pruritus: 
  0         1        2        3        4        5         6        7        8         9       10 
No itch                                                                                         severe itch 
 
2) Physician VAS for thickness: 
    0         1        2        3        4        5         6        7        8         9       10 
Flat                                                                                         highly raised 
 
3) Adverse effects: 
4) No of lesions: 
5) New lesions: 
 
WEEK 2: 
 
1) Patient VAS for pruritus: 
  0         1        2        3        4        5         6        7        8         9       10 
No itch                                                                                         severe itch 
 
  
2) Physician VAS for thickness: 
    0         1        2        3        4        5         6        7        8         9       10 
Flat                                                                                         highly raised 
 
3) Adverse effects: 
4) No of lesions: 
5) New lesions: 
 
FOLLOW –UP: 
 
 Week 4 Week 8 
New lesions   
Relapse   
Remission   
No change in lesions   
Itching   
 
 
RESPONSE: 
Cleared Mild 
Improvement 
 
Moderate 
Improvement 
Slight 
Improvement 
No 
response 
Exacerbation 
 
 

                         KEY TO MASTER SHEET 
 
AA Alopecia Areata 
BLD GRP  Blood Group 
bur Burning 
C Classical 
CLR Cleared 
DM Diabetes Mellitus 
DUR Duration 
E Exposed 
F Female 
fam Family History 
H Halobetasol 
HTN Hypertension 
HT Hypertrophic 
hypo Hypopigmentation 
L Linear 
LL Lower Limb 
M Male  
MAR Marked Improvement 
MOD Moderate Improvement 
mon months 
NE Non-Exposed 
NO CHG / NC No Change 
NL New Lesions 
P&S Palms and Soles 
REM Remission  
RE Relapse 
RESP Response 
side eff side effects 
skin dis  skin disorders 
SLI Slight Improvement 
T Tacrolimus 
THK Thickness 
THR Therapy 
UL Upper Limb 
yrs Years 
  
 
 
 
 
 
 
 
  
 
 
 
 
  
 
 
 
 
 
52%
48%
Sex Distribution
Male
Female
Age Distribution
10-20 years
20-30 years
30-40years
40-50 years
50-60 years
>60 years
  
 
 
 
 
 
62%
25%
10% 3%
Type of Lesion
Classical LP
Hypertrophic LP
Linear LP
Palmmoplantar LP
37%
9%
30%
5%
14%
2%
3%
Blood Group
O Positve
O Negative
A Positive
A Negative
B Postive
B Negative
AB Positive
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Clinician Assessment-Day 7
Halobetasol
Tacrolimus
0
2
4
6
8
10
12
Cleared Marked
Improvement
Moderate
Improvement
Slight
Improvement
No Change
N
o
. 
o
f 
P
a
t
ie
n
t
s
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sl.noSEX AGE BLD GRP TYPE SITE DUR E/NE DM HTN famly h/oTHR skin disordsi e eff
ITCH THK ITCHTHK RESP ITCH THK RESP RE NL NC REM RE NL NC REM
1 M 27 O +VE HT LL 1 yr E - - + H 8 9 7 5 SLI 3 4 MOD - + + - + + - - - -
2 M 42 O +VE C LL 2 mon UE - - - T 6 5 5 4 SLI 3 2 MOD - - + - - - + - - bur
3 F 62 O +VE C LL 1 mon E + - + H 7 5 4 2 MOD 1 1 MAR - + - - - + - - - -
4 M 51 A +VE C UL 6 mon UE - - - T 5 7 6 6 NO CHG 3 5 SLI - + - - - + - - vitiligo -
5 F 45 O +VE C LL 1.5 yrs UE - - - H 6 6 2 3 MAR 0 0 CLR - - - + + - - - - hypo
6 F 40 AB +VE C LL 3 mon UE - - - T 7 7 5 6 SLI 3 5 SLI - + - - - + - - - -
7 M 52 O -VE HT LL 2 yrs E - - - H 9 9 8 8 SLI 4 5 MOD - - + - - - + - vitiligo -
8 F 69 A+VE HT LL 2 mon E - - - T 9 9 9 10 NO CHG 7 7 SLI - + - - - + - - - bur
9 M 28 A+VE HT LL 1 yr E - - - H 10 9 5 6 MOD 3 4 MOD + - - - + + - - - -
10 M 41 B+VE C UL 6 mon UE - - - T 7 4 6 4 SLI 6 4 NO CHG - - + - - - + - vitiligo bur
11 M 15 AB +VE P&S P&S 6 mon E - - - H 9 8 4 5 MOD 1 2 MAR - - + - - - + - - hypo
12 M 35 B+VE C LL 2 yrs UE - - - T 7 7 6 7 NO CHG 5 7 NO CHG - - + - - - + - - -
13 M 18 A+VE L UL 4 mon E - - - H 6 5 1 2 MAR 0 0 CLR - - - + + - - - - -
14 M 13 B+VE C UL 1 yr E - - + T 7 7 6 6 SLI 2 5 SLI + - - - + - - - - bur
15 F 13 A+VE C LL 6 mon E - - - H 4 5 1 3 MAR 0 0 CLR - - - + - + - - - -
16 F 51 A+VE C UL 3 mon E - - + T 7 5 6 5 NO CHG 3 4 SLI - + - - - + - - - -
17 F 19 O+VE C UL 3 mon UE - - - H 6 6 3 3 MOD 2 3 MOD + - - - + - - - - hypo
18 M 61 O+VE HT LL 1 yr UE - - - T 6 10 5 10 SLI 3 10 SLI - - + - - - + - - -
19 M 14 A+VE C LL 3 weeks E - - - H 5 7 2 4 MOD 1 2 MAR - + - - - + - - - hypo
20 M 36 O+VE C UL 2 mon E - - - T 5 5 4 3 SLI 2 3 SLI - + - - - + - - - -
21 M 24 A+VE C UL 8 mon E - - - H 4 6 3 5 SLI 0 0 CLR - - - + - + - - - hypo
22 M 28 O+VE C LL 2 weeks E - - - T 2 5 1 4 SLI 0 0 CLR - - - + - - - + - bur
23 M 35 O+VE C CHEST 2 weeks UE - - - H 7 3 0 0 CLR 0 0 CLR - - - + - - - + - hypo
24 F 21 O+VE C UL 1 mon UE - - - T 6 5 3 3 MOD 3 1 MOD - + - - - + - - - bur
25 F 38 A+VE C LL 2 weeks UE - - - H 6 7 3 1 MAR 0 0 CLR - - - + - - - + - hypo
26 F 23 AB+VE C LL 2 mon E - - - T 6 4 3 2 MOD 1 0 MAR - - - + - - - + - -
27 F 45 O+VE C UL 2 mon E + - - H 5 6 3 3 MOD 2 2 MOD - + - - - + - - Vitiligo -
28 F 28 A+VE C UL 1 mon E - - - T 7 8 5 7 SLI 2 6 SLI - + - - - + - - - -
29 M 29 AB+VE C UL 3 mon E - - - H 4 5 3 3 SLI 1 2 MAR - - + - - - + - - -
30 M 25 O+VE L LL 1 mon UE - - - T 8 8 7 8 NO CHG 3 4 MOD - + - - - + - - - -
31 F 66 A+VE C UL 2 weeks UE + - - H 3 5 1 1 MAR 0 0 CLR - - - + - + - - - -
32 F 39 O-VE C UL 20 days E - - - T 2 2 1 1 MOD 0 0 CLR - - - + - - - + - bur
33 M 38 A+VE HT LL 6 mon E - - - H 9 9 8 8 NO CHG 4 6 SLI - + + - - - + - - hypo
34 M 56 O+VE C LL 6 mon UE + - - T 5 5 4 5 NO CHG 4 5 NO CHG - + + - - + + - - bur
35 F 35 AB+VE HT LL 2 mon E - - - H 9 10 4 8 MOD 2 5 MOD - + - - - + - - - -
36 F 14 A+VE HT LL 8 mon E - - - T 6 10 5 8 MOD 4 7 SLI - + - - - + - - - -
37 M 29 B+VE HT LL 3 mon E - - - H 10 10 10 9 NO CHG 6 7 SLI + - - - + - - - - -
38 F 35 O+VE C LL 1 mon E + - - T 8 6 3 4 MOD 0 3 MAR - - - + + - - - - -
39 F 25 O+VE L UL 2 mon UE - - - H 2 5 0 2 MAR 0 0 CLR - - - + - + - - - -
40 M 45 B+VE L LL 3 mon E + - - T 6 7 5 5 SLI 2 4 SLI - + - - - + - - - -
41 F 24 O+VE C TRUNK 1 mon UE - - - H 6 5 3 2 MOD 1 1 MAR - + - - - + - - - -
42 F 29 A+VE C UL 1 mon E - - - T 8 7 5 5 SLI 0 2 MAR - - - + - - - + - bur
43 F 40 O+VE C LL 3 mon UE - - - H 5 5 3 2 MOD 1 1 MAR - + - - - + - - - hypo
44 M 20 A+VE HT LL 1.5 yrs E - - - T 7 8 5 8 SLI 3 8 NO CHG - - + - - - + - - -
45 M 43 O-VE C UL 3 weeks E - - - H 1 3 0 1 MAR 0 0 CLR - - - + - - - + - -
46 M 32 O+VE L UL 4 mon E - - - T 4 5 2 3 MOD 0 1 MAR - - - + - + - - - -
47 M 46 B-VE C UL 9 mon E - - - H 3 4 1 4 MOD 0 1 MAR - + - - - + - - - -
48 F 43 A-VE HT LL 2 mon UE - - - T 10 9 9 9 NO CHG 5 9 NO CHG - - + - - - + - - bur
49 M 35 O+VE C LL 2 mon UE - - - H 5 5 3 3 MOD 2 2 MOD + + - - + - - - - hypo
50 F 32 A+VE C TRUNK 1.5 yrs E - - - T 4 6 4 6 NO CHG 2 6 NO CHG - - + - - - + - - -
51 M 36 B+VE HT LL 1.5 yrs E - - - H 9 10 8 7 SLI 1 7 MOD - - + - - - + - AA -
52 M 32 O-VE C UL 1 mon E - - - T 6 5 1 4 MOD 1 2 MAR - - - + - + - - - -
53 F 18 O-VE C UL 7 mon E - - - H 5 6 4 4 SLI 0 2 MAR - + - - - + - - - -
54 M 17 O+VE HT LL 1 yr E - - - T 10 9 7 9 SLI 5 8 SLI - - + - - - + - - bur
55 F 57 B+VE HT LL 6 mon E - - - H 8 8 7 7 SLI 4 6 SLI + - - - + - - - - -
1 MONTH 2 MONTHS0 WEEK 1 WEEK 2 WEEK
56 M 55 O+VE P&S P&S 3 mon E - - - T 5 5 4 3 SLI 2 2 MOD - + - - - + - - - -
57 F 34 A-VE C LL 2 mon E - - - H 5 4 0 2 MOD 0 0 CLR - - - + + - - - - hypo
58 F 59 O+VE C TRUNK 2 mon UE + - - T 6 6 5 4 SLI 3 2 MOD - + - - - + - - - -
59 F 43 A-VE HT LL 2 mon UE - - - H 8 9 7 8 SLI 6 7 SLI - - + - - - + - - -
60 F 17 B+VE L UL 5 mon E - - - T 2 4 2 4 NO CHG 2 4 NO CHG - - + - - + + - - bur
